Exact Sciences Corporation (NASDAQ:EXAS) Set to Announce Quarterly Earnings on Tuesday
Exact Sciences Corporation (NASDAQ:EXAS) is scheduled to release its earnings data before the market opens on Tuesday, July 25th. Analysts expect Exact Sciences Corporation to post earnings of ($0.36) per share for the quarter.
Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Thursday, April 27th. The medical research company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Exact Sciences Corporation had a negative return on equity of 49.24% and a negative net margin of 116.39%. The business had revenue of $48.36 million during the quarter, compared to analysts’ expectations of $37.38 million. During the same quarter last year, the company posted ($0.49) earnings per share. Exact Sciences Corporation’s quarterly revenue was up 225.9% on a year-over-year basis. On average, analysts expect Exact Sciences Corporation to post $-1.34 EPS for the current fiscal year and $-0.94 EPS for the next fiscal year.
Exact Sciences Corporation (EXAS) opened at 38.64 on Tuesday. The company’s market cap is $4.30 billion. Exact Sciences Corporation has a 12-month low of $11.96 and a 12-month high of $39.99. The company’s 50-day moving average price is $33.86 and its 200-day moving average price is $24.14.
TRADEMARK VIOLATION WARNING: “Exact Sciences Corporation (NASDAQ:EXAS) Set to Announce Quarterly Earnings on Tuesday” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/07/18/exact-sciences-corporation-nasdaqexas-set-to-announce-quarterly-earnings-on-tuesday.html.
In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the transaction, the senior vice president now owns 57,603 shares in the company, valued at $2,028,201.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is currently owned by insiders.
Several research firms have commented on EXAS. Cowen and Company reiterated an “outperform” rating and issued a $30.00 price objective on shares of Exact Sciences Corporation in a research note on Tuesday, April 4th. Vetr lowered shares of Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price target for the company. in a research note on Wednesday, July 12th. Canaccord Genuity raised their price target on shares of Exact Sciences Corporation from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Zacks Investment Research upgraded shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research note on Tuesday, June 27th. Finally, Goldman Sachs Group, Inc. (The) set a $33.00 price objective on shares of Exact Sciences Corporation and gave the stock a “neutral” rating in a report on Monday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Exact Sciences Corporation has an average rating of “Buy” and a consensus price target of $35.48.
About Exact Sciences Corporation
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.